VEGFA and neoplasm: This heightened angiogenic activity, primarily driven by VEGF and exacerbated by GSCs, is a major contributor to the aggressive nature of GB, presenting both challenges and opportunities for therapeutic interventions targeting the tumor vasculature [180].